This study is looking at the long-term safety of a drug called pirtobrutinib in people who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and have been treated before. You can join this study if you are actively participating in or have completed a previous study called J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038). The main goal is to see how many participants experience serious side effects (Grade 3 or higher) from pirtobrutinib. The study plans to enroll about 150 participants and will last approximately 5 years.

Study design

This is an interventional study with a planned enrollment of 150 participants. It is open to adults aged 18 and older.

What's involved

You will receive pirtobrutinib orally every 4 weeks. The study is expected to last about 5 years.

Compensation

Not stated in the trial record.

Follow-up

Your safety will be monitored from the first dose through 30 days after your last dose or the start of new anticancer therapy, whichever comes first.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.